Cover Image
Market Research Report

Skin Infections - Pipeline Review, H1 2014

Published by Global Markets Direct Product code 255953
Published Content info 183 Pages
Immediate Delivery Available
Price
Back to Top
Skin Infections - Pipeline Review, H1 2014
Published: June 15, 2014 Content info: 183 Pages
Description

Summary

Global Markets Direct's, 'Skin Infections - Pipeline Review, H1 2014', provides an overview of the Skin Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Skin Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Skin Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Skin Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Skin Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Skin Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Skin Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Skin Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Skin Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Product Code: GMDHC5101IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Skin Infections Overview
  • Therapeutics Development
    • Pipeline Products for Skin Infections - Overview
    • Pipeline Products for Skin Infections - Comparative Analysis
  • Skin Infections - Therapeutics under Development by Companies
  • Skin Infections - Therapeutics under Investigation by Universities/Institutes
  • Skin Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Skin Infections - Products under Development by Companies
  • Skin Infections - Products under Investigation by Universities/Institutes
  • Skin Infections - Companies Involved in Therapeutics Development
    • GlaxoSmithKline plc
    • Takeda Pharmaceutical Company Limited
    • Melinta Therapeutics, Inc
    • The Medicines Company
    • Toyama Chemical Co., Ltd.
    • Wockhardt Limited
    • Paratek Pharmaceuticals, Inc.
    • CrystalGenomics, Inc.
    • Debiopharm International S.A.
    • Bharat Biotech International Limited
    • MerLion Pharmaceuticals Pte Ltd
    • Foamix Ltd.
    • Anacor Pharmaceuticals, Inc.
    • Destiny Pharma Ltd.
    • Nabriva Therapeutics AG
    • Atox Bio Inc.
    • Cempra, Inc.
    • Cellceutix Corporation
    • Tetraphase Pharmaceuticals Inc.
    • Lytix Biopharma AS
    • Durata Therapeutics, Inc.
    • MGB Biopharma Limited
    • Pergamum AB
    • Furiex Pharmaceuticals, Inc.
    • Microbion Corporation
    • Biota Pharmaceuticals, Inc.
    • Lipid Pharmaceuticals ehf.
    • Dong-A Socio Holdings Co Ltd
  • Skin Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • dalbavancin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oritavancin disphosphate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ceftaroline fosamil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • delafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tedizolid phosphate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ozenoxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-1322322 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AFN-1252 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lysostaphin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • omadacycline tosylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brilacidin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • radezolid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CG-400549 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fusidic acid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LTX-109 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • minocycline - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AB-103 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • avarofloxacin hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • WCK-2349 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-2140944 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-7013 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-2718 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Bismuth ethanedithiol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-1450 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Skin Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DPD-207 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-04 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gyrase Program - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CaTx-II - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGB-BP-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • acALY18 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Skin and Soft Tissue and Community Acquired Pneumonia Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies Targeting ADAM10 for Dermatology, Infectious Diseases and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DBAF-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit 50S RNA for Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KBP-7072 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • siderocillin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • finafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptides to Activate TLR-2 for Oncology and Dermatology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit DHFR for cSSSI - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DPK-060 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eravacycline - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Skin Infections - Recent Pipeline Updates
  • Skin Infections - Dormant Projects
  • Skin Infections - Discontinued Products
  • Skin Infections - Product Development Milestones
    • Featured News & Press Releases
      • Apr 29, 2013: Durata Therapeutics Announces Presentation Of New Data Demonstrating In Vitro Potency Of Dalbavancin Against Bacterial Pathogens At 23rd Annual ECCMID Meeting
      • Dec 15, 2011: Rib-X Reports Positive Top-Line Data From Phase IIb Study Of Delafloxacin In Patients With Acute Bacterial Skin And Skin Structure Infections
      • Sep 15, 2011: Nabriva Therapeutics Presents Extended Phase II Results For Pleuromutilin Antibiotic BC-3781
      • Jun 06, 2011: Durata Therapeutics Announces Successful Production Of Clinical Supplies Of Dalbavancin
      • Apr 18, 2011: Nabriva Reports Positive Results from Phase II Trial Of Pleuromutilin Antibiotic BC-3781 In ABSSSI
      • Apr 18, 2011: Durata Therapeutics Initiates Phase III Study Of Dalbavancin For Treatment Of Acute Bacterial Skin And Skin Structure Infections
      • Apr 04, 2011: Cubist Pharma Settles CUBICIN Patent Litigation With Teva
      • Nov 29, 2010: The Medicines Company Reaches Agreement With FDA On SPA For Oritavancin Phase III Trials
      • Sep 07, 2010: Forest Receives FDA Advisory Committee Approval For Ceftaroline Fosamil For Treatment Of CABP And cSSSI
      • Sep 01, 2010: Lytix Biopharma Receives Hungarian Approval To Start Phase IIa Clinical Trial With Lytixar In Gram Positive Skin Infections
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Skin Infections, H1 2014
  • Number of Products under Development for Skin Infections - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Development by Companies, H1 2014 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Comparative Analysis by Unknown Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Development by Companies, H1 2014 (Contd..1)
  • Products under Development by Companies, H1 2014 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2014
  • Skin Infections - Pipeline by GlaxoSmithKline plc, H1 2014
  • Skin Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014
  • Skin Infections - Pipeline by Melinta Therapeutics, Inc, H1 2014
  • Skin Infections - Pipeline by The Medicines Company, H1 2014
  • Skin Infections - Pipeline by Toyama Chemical Co., Ltd., H1 2014
  • Skin Infections - Pipeline by Wockhardt Limited, H1 2014
  • Skin Infections - Pipeline by Paratek Pharmaceuticals, Inc., H1 2014
  • Skin Infections - Pipeline by CrystalGenomics, Inc., H1 2014
  • Skin Infections - Pipeline by Debiopharm International S.A., H1 2014
  • Skin Infections - Pipeline by Bharat Biotech International Limited, H1 2014
  • Skin Infections - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2014
  • Skin Infections - Pipeline by Foamix Ltd., H1 2014
  • Skin Infections - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014
  • Skin Infections - Pipeline by Destiny Pharma Ltd., H1 2014
  • Skin Infections - Pipeline by Nabriva Therapeutics AG, H1 2014
  • Skin Infections - Pipeline by Atox Bio Inc., H1 2014
  • Skin Infections - Pipeline by Cempra, Inc., H1 2014
  • Skin Infections - Pipeline by Cellceutix Corporation, H1 2014
  • Skin Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2014
  • Skin Infections - Pipeline by Lytix Biopharma AS, H1 2014
  • Skin Infections - Pipeline by Durata Therapeutics, Inc., H1 2014
  • Skin Infections - Pipeline by MGB Biopharma Limited, H1 2014
  • Skin Infections - Pipeline by Pergamum AB, H1 2014
  • Skin Infections - Pipeline by Furiex Pharmaceuticals, Inc., H1 2014
  • Skin Infections - Pipeline by Microbion Corporation, H1 2014
  • Skin Infections - Pipeline by Biota Pharmaceuticals, Inc., H1 2014
  • Skin Infections - Pipeline by Lipid Pharmaceuticals ehf., H1 2014
  • Skin Infections - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Skin Infections Therapeutics - Recent Pipeline Updates, H1 2014
  • Skin Infections - Dormant Projects, H1 2014
  • Skin Infections - Discontinued Products, H1 2014

List of Figures

  • Number of Products under Development for Skin Infections, H1 2014
  • Number of Products under Development for Skin Infections - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top